Sexual Health & Vitality

PT-141

$141.00

Per vial

$14.10

10 vials per pack

Suggested retail

$42.30

3× markup · per vial

Free shipping on orders over $2,000

$300 store credit on any independent COA · results don't matter

Milligrams Per Vial

Warehouse

Clear

Delivery guarantee Reshipped free if it doesn't arrive
≥99% purity Manufacturer-direct production
Independent COAs View COAs for this product →
Store credit guarantee Send any COA result, get store credit

PT-141 - Bremelanotide MC4R-Selective Melanocortin Research Peptide

PT-141 (bremelanotide) is a 7-amino-acid cyclic peptide derived from Melanotan 2 through metabolic cleavage. It was engineered specifically to isolate the MC4R-mediated central sexual-behavior signaling axis of the broader melanocortin system while removing the MC1R-driven melanogenesis axis. PT-141 is the reference MC4R-selective research melanocortin agonist and was FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women - making it one of the few melanocortin peptides with an approved-drug regulatory record.

Why the MC4R-Selective Profile Matters

The melanocortin receptor family has five subtypes. MC4R is the primary CNS sexual-behavior and appetite-regulation receptor, expressed heavily in the hypothalamus. Melanotan 2 binds all four relevant subtypes (MC1R, MC3R, MC4R, MC5R), producing a broad effect profile that includes skin pigmentation, appetite suppression, and MC4R-mediated sexual-behavior signaling. PT-141’s research distinction is that it largely isolates the MC4R signal - the sexual-behavior axis - without the MC1R melanogenesis component. That selectivity is what supports the Vyleesi approved-drug indication.

Pathway	What it does in plain terms
MC4R (hypothalamus)	Agonized - central sexual-behavior and arousal signaling
MC3R	Partial binding - secondary CNS melanocortin effects
MC1R (melanocyte)	Minimal - selectivity removes the pigmentation axis present in Melanotan 2
Route of administration	Subcutaneous in published clinical work (intranasal development was discontinued)

PT-141 vs Melanotan 2

The two compounds are compared constantly in the melanocortin research literature. PT-141 is literally derived from Melanotan 2, so the comparison is particularly clean.

Compound	Receptor profile
PT-141 (bremelanotide)	MC4R-selective - isolates CNS sexual-behavior axis
Melanotan 2	Broad - binds MC1R / MC3R / MC4R / MC5R; includes melanogenesis + libido + appetite
Melanotan 1 (afamelanotide)	MC1R-selective - isolates melanogenesis axis (EPP indication)

Research Applications

PT-141 is used in studies examining:

MC4R agonism and central sexual-behavior signaling endpoints
Hypoactive sexual desire disorder (HSDD) research models
Erectile function and central arousal pathway research
Comparative melanocortin-selectivity research (PT-141 vs Melanotan 2 vs Melanotan 1)
Hypothalamic melanocortin signaling biology
Non-pigmentation melanocortin-axis research

Specifications


Format	Lyophilized powder
Purity	≥99%
Aliases	Bremelanotide, PT 141, Vyleesi
Available sizes	10mg
Storage	2-8°C unopened; stable 12+ months
Use	Research purposes only - not for human use

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for PT-141 are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical PT-141 literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About PT-141 Research

What is PT-141 used for in research?

It is studied as the reference MC4R-selective melanocortin agonist. Published work covers central sexual-behavior signaling endpoints, hypoactive sexual desire disorder (HSDD) models, erectile-function research, and comparative melanocortin-selectivity research against Melanotan 2 and Melanotan 1.

What is the difference between PT-141 and Melanotan 2?

PT-141 (bremelanotide) was derived from Melanotan 2 by metabolic cleavage. PT-141 is MC4R-selective - it retains the central sexual-behavior axis without the MC1R melanogenesis component. Melanotan 2 binds all melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R), producing a broader effect profile that includes skin pigmentation in addition to libido and appetite endpoints.

Is PT-141 FDA approved?

Yes - PT-141 (bremelanotide) is FDA approved as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women. Research-grade PT-141 is not sold under the Vyleesi brand and is distinct from the approved drug product. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

Does PT-141 cause skin pigmentation like Melanotan 2?

In published research, PT-141’s MC4R selectivity means it has minimal activity at MC1R (the melanocyte receptor), so the pigmentation axis that is prominent with Melanotan 2 is largely removed. This is the specific research reason PT-141 was developed from Melanotan 2 - to retain the central sexual-behavior signaling while removing the melanogenesis axis.

How is PT-141 stored?

Unopened vials are stored at 2-8°C and stay stable for 12+ months. Once reconstituted with bacteriostatic water, the solution is kept at 2-8°C and used within 28-30 days.

Purity Guarantee

Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.